Table 2.
Demographic and other baseline characteristics
| |
Arm A |
Arm B |
Arm C |
Arm D |
Overall |
|
|---|---|---|---|---|---|---|
| (N=60) | (N=64) | (N=58) | (N=59) | (N=241) | ||
|
Age (years) |
|
|
|
|
|
|
| Median (Range) |
58.5 (37-76) |
57.5 (31-74) |
56 (38-77) |
55 (33-76) |
57 (31-77) |
|
| |
N (%) |
N (%) |
N (%) |
N (%) |
N (%) |
|
| Ethnic Origin, N (%) |
Caucasian |
58 (96.6) |
63 (98.4) |
58 (100) |
59 (100) |
238 (98.8) |
| African |
1 (1.7) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.4) |
|
| Asian |
1 (1.7) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.4) |
|
| Othera |
0 (0.0) |
1 (1.6) |
0 (0.0) |
0 (0.0) |
1 (0.4) |
|
| Menopausal status, N (%) |
pre |
19 (31.7) |
17 (26.6) |
16 (27.6) |
21 (35.6) |
73 (30.3) |
| post |
41 (68.3) |
47 (73.4) |
42 (72.4) |
38 (64.4) |
168 (69.7) |
|
|
Karnofsky Performance Status, N (%) |
Point |
|
|
|
|
|
| Able to care for self |
70 |
0 (0.0) |
0 (0.0) |
2 (3.5) |
2 (3.4) |
4 (1.66) |
| Normal activity but requiring effort |
80 |
5 (8.3) |
3 (4.7) |
5 (8.6) |
7 (11.9) |
20 (8.3) |
| Able to carry on normal activity |
90 |
11 (18.3) |
16 (25.0) |
9 (15.5) |
15 (25.4) |
51 (21.2) |
| Normal |
100 |
44 (73.3) |
44 (68.8) |
41 (70.7) |
35 (59.3) |
164 (68.0) |
| Not done |
|
0 (0.0) |
1 (1.56) |
1 (1.72) |
0 (0.0) |
2 (0.8) |
| Hormonal receptor status, N (%) |
ER+ |
44 (73.3) |
47 (73.4) |
39 (67.2) |
46 (78.0) |
176 (73.0) |
| PR+ |
38 (63.3) |
43 (67.2) |
34 (58.6) |
42 (71.2) |
157 (65.1) |
|
| Previous hormonal therapy, N (%) |
Yes |
44 (73.7) |
48 (75.0) |
40 (69.0) |
46 (78.0) |
178 (73.9) |
| No |
16 (26.7) |
16 (25.0) |
17 (29.3) |
13 (22.0) |
62 (25.7) |
|
| Visceral metastases, N (%) |
Absence |
19 (31.7) |
19 (29.7) |
16 (27.6) |
23 (39.0) |
77 (32.0) |
| Presence |
41 (68.3) |
45 (70.3) |
42 (72.4) |
36 (61.0) |
164 (68.0 |
|
| Previous adjuvant/neoadjuvant taxane therapyb, N (%) |
Yes |
21 (35.0) |
24 (37.5) |
12 (20.7) |
19 (32.2) |
76 (31.5) |
| No | 39 (65.0) | 40 (62.5) | 45 (77.6) | 40 (67.8) | 164 (68.0) | |
aOther: 1 Creole; b1 patient in Arm C had no record for previous hormonal therapy and adjuvant/neoadjuvant therapy.
Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.
PR: Partial Response.